No association was found among atherosclerosis and serum phosphorus, FGF23, or PTH levels, indicating that, in this CKD cohort, those CKD-MBD parameters were not useful to predict elevated cIMT or plaque prevalence, in accordance with previous studies [31], showing that those parameters might change at a different pace in CKD progression or, maybe, by an effective management of CKD patients. The gene discussed is PTH; the disease is Marchiafava-Bignami disease.